Radiopharm Theranostics Ltd (RADX) Shares Outstanding (2023 - 2025)
Radiopharm Theranostics (RADX) posted quarterly Shares Outstanding (Entity) of $2.4 billion for Q2 2025, up 413.71% year-over-year from $460.4 million in Q2 2024, and up 413.71% quarter-over-quarter from $460.4 million in Q2 2024.
Radiopharm Theranostics Ltd (RADX) Shares Outstanding (2023 - 2025) Analysis & Trends
Radiopharm Theranostics (RADX) has reported Shares Outstanding (Entity) for 3 consecutive years, with $2.4 billion the latest figure, recorded in Q2 2025.
- In Q2 2025, Shares Outstanding (Entity) rose 413.71% year-over-year to $2.4 billion; the TTM figure through Jun 2025 stood at $2.4 billion (up 413.71% YoY), while the FY2025 annual figure was $2.4 billion, up 413.71% from the prior year.
- Shares Outstanding (Entity) climbed to $2.4 billion in Q2 2025 per RADX's latest filing, from $460.4 million in the prior quarter.
- Across five years, Shares Outstanding (Entity) topped out at $2.4 billion in Q2 2025 and bottomed at $339.3 million in Q2 2023.
- Historically, Shares Outstanding (Entity) has averaged $1.1 billion across 3 years, with a median of $460.4 million in 2024.
- Annual changes were most pronounced in 2024 — Shares Outstanding (Entity) soared 35.68% — and 2025, when it soared 413.71%.
- Radiopharm Theranostics' Shares Outstanding (Entity) stood at $339.3 million in 2023, then jumped by 35.68% to $460.4 million in 2024, then jumped by 413.71% to $2.4 billion in 2025.
- Business Quant data shows RADX's Shares Outstanding (Entity) at $2.4 billion in Q2 2025, $460.4 million in Q2 2024, and $339.3 million in Q2 2023.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 2.08 Bn |
| Jun 30, 2024 | 386.46 Mn |
| Jun 30, 2023 | 305.83 Mn |